Journal: CPT: pharmacometrics & systems pharmacology
This study conducted a model-based meta-analysis (MBMA) to evaluate the effects of pembrolizumab on patient-reported quality of life (QoL) across multiple cancer types using longitudinal EORTC QLQ-C30 data from clinical trials.
Despite mixed results in original studies, the modeling approach revealed:
- Increased toxicity associated with pembrolizumab.
- Improved long-term QoL compared to controls.
The analysis detected treatment effects on QoL that traditional statistical methods missed. This demonstrates that MBMA combined with population modeling offers a more precise assessment of patient-reported outcomes.
This method supports integrating patient-centered data into oncology drug development and regulatory decisions.